Department of Medical Genomics, Centre for Genomics Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; Department of Clinical Genomics, Mayo Clinic, Rochester, MN, United States; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Department of Clinical Genomics, Mayo Clinic, Rochester, MN, United States.
Mol Genet Metab. 2023 Nov;140(3):107688. doi: 10.1016/j.ymgme.2023.107688. Epub 2023 Aug 23.
Biallelic pathogenic variants in PGAP3 cause a rare glycosylphosphatidyl-inositol biogenesis disorder, PGAP3-CDG. This multisystem condition presents with a predominantly neurological phenotype, including developmental delay, intellectual disability, seizures, and hyperphosphatemia. Here, we summarized the phenotype of sixty-five individuals including six unreported individuals from our CDG natural history study with a confirmed PGAP3-CDG diagnosis. Common additional features found in this disorder included brain malformations, behavioral abnormalities, cleft palate, and characteristic facial features. This report aims to review the genetic and metabolic findings and characterize the disease's phenotype while highlighting the necessary clinical approach to improve the management of this rare CDG.
PGAP3 中的双等位基因致病性变异导致一种罕见的糖基磷脂酰肌醇生物发生障碍,即 PGAP3-CDG。这种多系统疾病主要表现为神经表型,包括发育迟缓、智力残疾、癫痫发作和高磷酸血症。在这里,我们总结了 65 名患者的表型,包括我们的 CDG 自然病史研究中未报告的 6 名患者,这些患者均被确诊为 PGAP3-CDG。该疾病还常见其他特征,包括脑畸形、行为异常、腭裂和特征性面部特征。本报告旨在回顾该疾病的遗传学和代谢学发现,并描述其表型特征,同时强调了改善这种罕见的 CDG 管理的必要临床方法。